Antibody–drug conjugate combinations take center stage in recent urothelial cancer advancements

Key Points

• To report recent advancements in urothelial cancer treatments, focusing on antibody-drug conjugate combinations and their outcomes.
• Review of recent major cancer therapy advancements
• Analysis of survival data from various treatment regimens
• Comparison of antibody-drug conjugates with traditional chemotherapy
• Overall survival nearly doubled with disitamab vedotin plus toripalimab compared to chemotherapy
• Nine-year data shows sustained benefit of nivolumab in high-risk resected melanoma
• Zanzalintinib plus atezolizumab was the first immunotherapy to show benefits in metastatic colorectal cancer.

Abstract